Obesity hinders treatment in pediatric leukemia

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 10
Volume 18
Issue 10

Obesity may contribute to chemotherapy resistance and increasing relapse rates among children with leukemia, an animal study in Cancer Research (online, September 22, 2009) suggests.

Obesity may contribute to chemotherapy resistance and increasing relapse rates among children with leukemia, an animal study in Cancer Research (online, September 22, 2009) suggests.

Steven D. Mittelman, MD, PhD, and colleagues developed a mouse model of obesity and leukemia for which they cultured fat and leukemia cells together, and treated the leukemia cells with traditional chemotherapy drugs used in children: vincristine, nilotinib (Tasigna), daunorubicin, and dexamethasone.

According to the results, obese mice with leukemia had higher relapse rates than lean mice after treatment with the first-line chemotherapeutic agent vincristine. The chemotherapy treatments all worked less effectively in culture when fat cells were nearby. When the mice relapsed from the leukemia, the researchers found leukemia "hiding out" in the fat tissue during chemotherapy, said Dr. Mittelman's group, based at Children's Hospital Los Angeles and the Keck School of Medicine at the University of Southern California.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content